Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 57,734 | 66,634 | 56,561 | 54,251 | 60,625 |
| TOTAL | $60,162 | $68,686 | $59,055 | $56,838 | $63,351 |
| Non-Current Assets | |||||
| PPE Net | 153 | 129 | 134 | 139 | 144 |
| Other Non-Current Assets | 182 | 191 | 201 | 211 | 260 |
| TOTAL | $335 | $321 | $335 | $349 | $403 |
| Total Assets | $60,496 | $69,006 | $59,390 | $57,188 | $63,754 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,253 | 6,001 | 6,983 | 5,367 | 4,415 |
| Accrued Expenses | 1,947 | 1,714 | 2,425 | 3,733 | 3,376 |
| TOTAL | $15,675 | $15,064 | $13,630 | $9,154 | $7,904 |
| Non-Current Liabilities | |||||
| Long Term Debt | 13,810 | 16,651 | 19,506 | 23,413 | 23,254 |
| TOTAL | $13,903 | $16,760 | $19,629 | $23,550 | $23,406 |
| Total Liabilities | $29,578 | $31,823 | $33,259 | $32,704 | $31,310 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 36,820 | 36,679 | 36,679 | 31,108 | 30,868 |
| Common Shares | 12 | 12 | 11 | 10 | 10 |
| Retained earnings | -163,432 | -155,104 | -144,501 | -133,602 | -122,753 |
| TOTAL | $30,918 | $37,183 | $26,131 | $24,484 | $32,444 |
| Total Liabilities And Equity | $60,496 | $69,006 | $59,390 | $57,188 | $63,754 |